Aidence was acquired in 2022 by RadNet, Inc., a leading provider of diagnostic imaging in
the United States, then integrated into DeepHealth, a wholly owned subsidiary of
RadNet. With a
mission to empower breakthroughs in care through imaging, DeepHealth builds on and enhances the
capabilities of the companies it has integrated and rebranded. As a global leader in AI-powered
health informatics, DeepHealth aims to push the boundaries of what’s possible in healthcare by
leveraging advanced AI to enable operational efficiency, clinical confidence, and better
delivery of care, while elevating the experience for care teams through human-centered,
intuitive technology.
Founded in 2015, Aidence was a radiology AI company focused on clinical solutions for
pulmonary nodule management in routine practice and lung cancer screening. The company
developed
and deployed AI clinical applications to empower radiologists and other physicians in
interpreting medical images. Their first commercialized product, Veye Lung Nodules (now
DeepHealth Lung) was an AI-based solution for lung nodule detection
classification,
quantification, and growth assessment. This solution has been CE marked in Europe.
2015
Aidence founded in Amsterdam
2017
CE mark for Veye Lung Nodules
2022
Aidence acquired by RadNet
2023
Aidence becomes part of DeepHealth
DeepHealth Lung
DeepHealth
Lung
is an AI-powered nodule detection, reporting, and patient management for enhanced efficiency and accuracy in lung
cancer diagnosis.
DeepHealth proudly serves as a Gold Sponsor for the British Institute of Radiology's 8th Annual AI Congress, demonstrating our commitment to advancing AI applications in medical imaging. Join us for live demonstrations of our diagnostic and clinical AI solutions. This year's Congress showcases AI in the NHS, addressing critical topics including AI strategy, government policy, ethics, governance, post-market surveillance, and future scoping—all areas where DeepHealth's solutions offer significant value to healthcare providers.
Join DeepHealth at the 31st ESTI Annual Scientific Meeting to explore our AI-powered thoracic imaging solutions. With the meeting's focus on practical AI applications, discover how our advanced algorithms enhance diagnostic capabilities for lung screening. Our team will demonstrate seamless integration with existing workflows and show how leading European institutions are leveraging DeepHealth's technology to transform chest imaging and improve patient outcomes.
Los Angeles, CA and Nashua, NH – April 15, 2025, RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, and iCAD, Inc. (NASDAQ: ICAD) (“iCAD”), a global leader in providing clinically proven AI-powered breast health solutions, announced today that they have entered into a definitive merger agreement under which RadNet will acquire iCAD in an all stock transaction.
Disclaimers:
DeepHealth Lung is manufactured as Veye Lung Nodules by Aidence BV for DeepHealth Inc. Not all products and
functionalities are commercially
available in all countries. For
clearance and commercial availability in your geography of functionalities listed and compatibility with other
systems, please contact us.